The Non-Alcoholic Steatohepatitis and Cardiovascular Disease Intersection, an Important Consideration in Drug Development

by Seth Baum, Barton Isaac, Rebecca Taub, Stephen A. Harrison
Published 2020-09-01

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

by Stephen A. Harrison, Mustafa Bashir, Sam E. Moussa, Kevin McCarty, Juan Pablo Frias, Rebecca Taub, Naim Alkhouri
Published 2021-04-01